# Revisiting Bill Lands’ Hypotheses: HUFA Balance, Immuno-Metabolic Regulation, and Conflicting Clinical Evidence

**Authors:** Ulrich Suchner

PMC · DOI: 10.3390/nu18040626 · 2026-02-13

## TL;DR

This paper reviews Bill Lands' hypothesis on the balance of n-6 and n-3 fatty acids in diets and their impact on health, suggesting it could influence chronic disease prevention.

## Contribution

The paper synthesizes Lands' work and evaluates evidence for his hypotheses on PUFA balance and inflammation, calling for renewed investigation.

## Key findings

- High n-6 PUFA intake may shift n-3-derived pathways and eicosanoid signaling.
- Western diets can lead to up to 80% n-6 HUFA in tissues, contrasting with traditional diets.
- The hypothesis remains unresolved and requires further systematic study for public health implications.

## Abstract

The optimal dietary balance between n-6 and n-3 polyunsaturated fatty acids (PUFAs), the safe upper intake of n-6 PUFAs—particularly linoleic acid—and the physiological consequences of their metabolic competition remain unresolved in the context of the Western diet. Since the 1980s, Bill Lands and colleagues have argued that high n-6 PUFA intake can shift the balance of n-3-derived pathways and eicosanoid signaling, potentially influencing processes relevant to non-communicable diseases. Across human populations, the proportion of n-6 in tissue HUFA spans a broad range—from roughly 20% in traditional dietary patterns to nearly 80% in typical Western diets—illustrating the predictable impact of dietary precursor supply on HUFA composition. Despite its potential public health implications, this hypothesis has received limited systematic attention. In this narrative review, we synthesize key aspects of Lands’ work, evaluate supportive and contradictory evidence, and highlight mechanistic insights into lipid competition and inflammatory regulation. We conclude that these unresolved but testable hypotheses warrant renewed investigation, as their corroboration could reshape dietary guidelines and strategies for chronic disease prevention.

## Linked entities

- **Chemicals:** linoleic acid (PubChem CID 5280450)

## Full-text entities

- **Genes:** PPARD (peroxisome proliferator activated receptor delta) [NCBI Gene 5467] {aka FAAR, NR1C2, NUC1, NUCI, NUCII, PPARB}, LOX (lysyl oxidase) [NCBI Gene 4015] {aka AAT10}, FADS1 (fatty acid desaturase 1) [NCBI Gene 3992] {aka D5D, FADS6, FADSD5, LLCDL1, TU12}, FADS2 (fatty acid desaturase 2) [NCBI Gene 9415] {aka D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, CNBP (CCHC-type zinc finger nucleic acid binding protein) [NCBI Gene 7555] {aka CNBP1, DM2, PROMM, RNF163, ZCCHC22, ZNF9}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, COX8A (cytochrome c oxidase subunit 8A) [NCBI Gene 1351] {aka COX, COX8, COX8-2, COX8L, MC4DN15, VIII}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, PLA2G1B (phospholipase A2 group IB) [NCBI Gene 5319] {aka PLA2, PLA2A, PPLA2}, FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, PPIG (peptidylprolyl isomerase G) [NCBI Gene 9360] {aka CARS-Cyp, CYP, SCAF10, SRCyp}
- **Diseases:** chronic migraine (MESH:D008881), hepatic lipid (MESH:D011017), metabolic dysregulation (MESH:D021081), metabolic disease (MESH:D008659), Chronic Disease (MESH:D002908), back and neck pain (MESH:D019547), cognitive decline (MESH:D003072), kidney disease (MESH:D007674), depression (MESH:D003866), obesity (MESH:D009765), chronic pain (MESH:D059350), colorectal polyps (MESH:D003111), type 2 diabetes (MESH:D003924), fatty liver disease (MESH:D005234), loss of lean mass (MESH:D013851), stroke (MESH:D020521), cardiac and retinal disorders (MESH:D012164), NCDs (MESH:D000073296), allergy (MESH:D004342), endothelial dysfunction (MESH:D014652), immune dysfunction (MESH:D007154), diabetic (MESH:D003920), ischemic stroke (MESH:D002544), cancer (MESH:D009369), preterm birth (MESH:D047928), CVD (MESH:D002318), NAFLD (MESH:D065626), infection (MESH:D007239), anxiety (MESH:D001007), Toxicity (MESH:D064420), peripheral vascular disease (MESH:D016491), platelet aggregation (MESH:D001791), thrombosis (MESH:D013927), metabolic, cardiovascular, pulmonary, and immune-related disorders (MESH:D024821), gastroesophageal reflux disease (MESH:D005764), injury to (MESH:D014947), diseases (MESH:D004194), arthritis (MESH:D001168), inflammation (MESH:D007249), essential fatty acid deficiency (MESH:D008067), sarcopenia (MESH:D055948), headache (MESH:D006261), muscle (MESH:D019042), atherosclerosis (MESH:D050197), coronary heart disease (MESH:D003327), hypertension (MESH:D006973), lipid metabolism (MESH:D052439)
- **Chemicals:** epoxides (MESH:D004852), 4-hydroxynonenal (MESH:C027576), vegetable oils (MESH:D010938), glucose (MESH:D005947), cholesterol (MESH:D002784), trans fatty acids (MESH:D044242), 18:3n-3 (MESH:D017962), oxylipin (MESH:D054883), EPA (MESH:D015118), phospholipid (MESH:D010743), thromboxane (MESH:D013931), alpha-tocopherol (MESH:D024502), sterol (MESH:D013261), DHA (MESH:D004281), lipopolysaccharide (MESH:D008070), heptanoic acid (MESH:D006538), ARA (MESH:D016718), Lipid (MESH:D008055), PG (MESH:D011453), n (MESH:D009584), leukotriene (MESH:D015289), 8-hydroxyoctanoic acid (MESH:C083377), n-3 PUFA (MESH:D015525), oils (MESH:D009821), Fatty Acid (MESH:D005227), PC (MESH:D010713), essential fatty acid (MESH:D005228), triglyceride (MESH:D014280), HETE (MESH:D006893), LA (MESH:D019787), lipoxin (MESH:D044045), PE (MESH:C483858), 22:5n-3 (MESH:C026219), 18-carbon PUFA (-), eicosanoid (MESH:D015777), 18:4n-3 (MESH:C062895), HEPE (MESH:D006531), PUFA (MESH:D005231), soybean oil (MESH:D013024), LTB4 (MESH:D007975), phosphoglycerides (MESH:D020404)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606], Glycine max (soybean, species) [taxon 3847]
- **Mutations:** rs66698963

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943793/full.md

---
Source: https://tomesphere.com/paper/PMC12943793